Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 23598371)

1.

Randomised trial on episodic cluster headache with an angiotensin II receptor blocker.

Tronvik E, Wienecke T, Monstad I, Dahløf C, Bøe MG, Tjensvoll AB, Salvesen R, Zwart JA, Jansson SO, Stovner LJ.

Cephalalgia. 2013 Sep;33(12):1026-34. doi: 10.1177/0333102413484989. Epub 2013 Apr 18.

PMID:
23598371
2.

Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G.

JAMA. 2003 Jan 1;289(1):65-9.

PMID:
12503978
3.

Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003).

Sandset EC, Murray G, Boysen G, Jatuzis D, Kõrv J, Lüders S, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group.

Int J Stroke. 2010 Oct;5(5):423-7. doi: 10.1111/j.1747-4949.2010.00473.x.

PMID:
20854630
4.

ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.

Flesch M, Knipp S, Kessler G, Geissler HJ, Massoudy P, Wilhelm H, Philipp T, Erdmann E.

Clin Res Cardiol. 2009 Jan;98(1):33-43. doi: 10.1007/s00392-008-0719-9. Epub 2008 Oct 13.

PMID:
18853093
5.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
6.

Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial.

Leroux E, Valade D, Taifas I, Vicaut E, Chagnon M, Roos C, Ducros A.

Lancet Neurol. 2011 Oct;10(10):891-7. doi: 10.1016/S1474-4422(11)70186-7. Epub 2011 Sep 6.

PMID:
21903477
7.

Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.

Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group.

Heart. 2011 Mar;97(6):479-84. doi: 10.1136/hrt.2009.192104. Epub 2011 Feb 4.

PMID:
21296780
8.
9.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.

Gales BJ, Bailey EK, Reed AN, Gales MA.

Ann Pharmacother. 2010 Feb;44(2):360-6. doi: 10.1345/aph.1M312. Epub 2010 Jan 19. Review.

PMID:
20086184
10.

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.

Radke PW, Figulla HR, Drexler H, Klues HG, Mügge A, Silber S, Daniel W, Schmeisser A, Reifart N, Motz W, Büttner HJ, Fischer D, Ortlepp JR, Schaefers K, Hoffmann R, Hanrath P; AACHEN Trial Investigators.

Am Heart J. 2006 Oct;152(4):761.e1-6.

PMID:
16996855
11.

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.

Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E; CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.

J Hypertens. 2005 Feb;23(2):435-44.

PMID:
15662233
12.

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators.

N Engl J Med. 2006 Apr 20;354(16):1685-97. Epub 2006 Mar 14.

13.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).

Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators.

Eur Heart J. 2009 May;30(10):1203-12. doi: 10.1093/eurheartj/ehp101. Epub 2009 Apr 4.

14.

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).

Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A; Study on Cognition and Prognosis in the Elderly study group.

J Am Coll Cardiol. 2004 Sep 15;44(6):1175-80.

15.

A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.

Clin Drug Investig. 2007;27(6):407-17.

PMID:
17506591
16.

The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.

Perrin NE, Jaremko GA, Berg UB.

Pediatr Nephrol. 2008 Jun;23(6):947-54. doi: 10.1007/s00467-008-0745-x.

PMID:
18270751
17.

Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.

Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, Lièvre M, Heemann U, Legendre C.

Nephrol Dial Transplant. 2010 Mar;25(3):967-76. doi: 10.1093/ndt/gfp581. Epub 2009 Nov 3.

18.

Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.

Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kim JA, Lee Y, Shin EK.

Diabetes Care. 2006 Feb;29(2):195-201.

PMID:
16443859
19.
20.

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.

Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA; CHARM investigators.

Lancet. 2005 Dec 10;366(9502):2005-11.

PMID:
16338449
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk